Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Completed 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Plasma cell 240Lymphoid 27Other hematologic neoplasm 25Genitourinary 5Thoracic 4Myeloid 3Breast 3Gastrointestinal 2CNS 2Tumor-Agnostic 1Other solid neoplasm 1Other neoplasm 1Dermatologic 1Classical hematology 1

Conditions

Prostatic Neoplasms 2Multiple Myeloma 2Acute Kidney Injury 2Urologic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 289enzalutamide 283Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 252Abiraterone Acetate 217Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 117Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 106cabozantinib 104atezolizumab 104Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
daratumumab × Genitourinary × Clear all
NCT06549634 2026-02-27

Biomarkers of AKI in Patients Receiving Daratumumab

Brigham and Women's Hospital

Completed
20 enrolled
GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT06483139 2025-11-19

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Brigham and Women's Hospital

Recruiting
450 enrolled
GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT03473730 2025-01-30

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
17 enrolled
Genitourinary

Carcinoma, Renal Cell, Urologic Neoplasms

NCT03035357 2024-05-03

Neoadjuvant Listeria or Daratumumab in Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT03177460 2024-05-03

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
33 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡